Targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and engraftment in older patients with active, relapsed, or refractory (rel/ref) AML: Preliminary midpoint results from the prospective, randomized phase 3 SIERRA trial Meeting Abstract
| Authors: | Gyurkocza, B.; Nath, R.; Stiff, P.; Agura, E.; Litzow, M.; Tomlinson, B.; Choe, H.; Abhyankar, S.; Seropian, S.; Chen, G.; Hari, P.; Al-Kadhimi, Z.; Foran, J.; Orozco, J.; Van Besien, K.; Sabloff, M.; Kebriaei, P.; Abboud, C.; Levy, M. Y.; Lazarus, H.; Giralt, S.; Berger, M.; Reddy, V.; Pagel, J. |
| Abstract Title: | Targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and engraftment in older patients with active, relapsed, or refractory (rel/ref) AML: Preliminary midpoint results from the prospective, randomized phase 3 SIERRA trial |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | leukemia; hematopoietic stem cell; aml; acute myeloid; reduced; transplantation (hct); relapsed/refractory (rel/ref) aml; iodine (i-131) apamistamab [iomab-b]; intensity conditioning (ric); conventional care (cc) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S182 |
| Language: | English |
| ACCESSION: | WOS:000564055100086 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30716-3 |
| Notes: | Meeting Abstract: AML-123 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
